Relmada Therapeutics (STU:4E2) 3-Year EBITDA Growth Rate : 4.10% (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Relmada Therapeutics 3-Year EBITDA Growth Rate?

Relmada Therapeutics's EBITDA per Share for the three months ended in Mar. 2024 was €-0.70.

During the past 3 years, the average EBITDA Per Share Growth Rate was 4.10% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was -18.10% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was -57.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 11 years, the highest 3-Year average EBITDA Per Share Growth Rate of Relmada Therapeutics was 31.60% per year. The lowest was -786.50% per year. And the median was -28.70% per year.

Competitive Comparison of Relmada Therapeutics's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, Relmada Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Relmada Therapeutics's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Relmada Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Relmada Therapeutics's 3-Year EBITDA Growth Rate falls into.

Relmada Therapeutics 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Relmada Therapeutics (STU:4E2) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Relmada Therapeutics 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Relmada Therapeutics's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Relmada Therapeutics (STU:4E2) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Relmada Therapeutics Inc (STU:4E2) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

RLMD:USA

Address

2222 Ponce de Leon Boulevard, Floor 3, Coral Gables, FL, USA, 33134

Website

https://www.relmada.com

Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.

Relmada Therapeutics (STU:4E2) Headlines

No Headlines